Philippe A. Cassier
About
Philippe A. Cassier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Philippe A. Cassier has authored 295 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Oncology, 125 papers in Pulmonary and Respiratory Medicine and 60 papers in Molecular Biology. Recurrent topics in Philippe A. Cassier's work include Sarcoma Diagnosis and Treatment (51 papers), Cancer Immunotherapy and Biomarkers (49 papers) and Gastrointestinal Tumor Research and Treatment (46 papers). Philippe A. Cassier is often cited by papers focused on Sarcoma Diagnosis and Treatment (51 papers), Cancer Immunotherapy and Biomarkers (49 papers) and Gastrointestinal Tumor Research and Treatment (46 papers). Philippe A. Cassier collaborates with scholars based in France, United States and Spain. Philippe A. Cassier's co-authors include Jean‐Yves Blay, Isabelle Ray‐Coquard, Antoîne Italiano, David Pérol, Jean‐Pierre Delord, Armelle Dufresne, Axel Le Cesne, Leisha A. Emens, Marcella Fassò and Joseph P. Eder and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Philippe A. Cassier
275 papers receiving 7.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Philippe A. Cassier France | 43 | 4.0k | 3.2k | 1.4k | 1.1k | 1.1k | 295 | 7.4k | ||
| Annick D. Van den Abbeele United States | 43 | 3.3k 0.8× | 4.4k 1.3× | 1.5k 1.0× | 502 0.4× | 1.8k 1.6× | 146 | 8.8k | ||
| Didier Cupissol France | 36 | 4.9k 1.2× | 4.4k 1.4× | 1.6k 1.1× | 584 0.5× | 2.5k 2.2× | 160 | 8.9k | ||
| Sant P. Chawla United States | 50 | 3.9k 1.0× | 5.4k 1.7× | 1.9k 1.4× | 540 0.5× | 1.4k 1.3× | 300 | 9.7k | ||
| Emmanuelle Bompas France | 38 | 2.6k 0.7× | 4.1k 1.3× | 784 0.5× | 448 0.4× | 912 0.8× | 197 | 5.8k | ||
| Scott M. Schuetze United States | 43 | 3.3k 0.8× | 6.4k 2.0× | 1.4k 0.9× | 415 0.4× | 1.3k 1.1× | 167 | 8.7k | ||
| Scott H. Okuno United States | 42 | 2.5k 0.6× | 3.6k 1.1× | 959 0.7× | 267 0.2× | 1.2k 1.0× | 178 | 5.8k | ||
| Talia Golan Israel | 39 | 5.4k 1.4× | 1.7k 0.5× | 2.0k 1.4× | 1.1k 0.9× | 975 0.9× | 170 | 7.2k | ||
| CDM Fletcher United States | 10 | 2.3k 0.6× | 2.6k 0.8× | 1.3k 0.9× | 431 0.4× | 1.9k 1.7× | 16 | 7.3k | ||
| Manuel Rodriguez‐Justo United Kingdom | 45 | 1.9k 0.5× | 1.2k 0.4× | 1.4k 1.0× | 619 0.5× | 2.5k 2.2× | 174 | 6.4k | ||
| Jonathan C. Trent United States | 48 | 2.5k 0.6× | 5.1k 1.6× | 1.3k 0.9× | 388 0.3× | 2.2k 2.0× | 283 | 8.2k |
Countries citing papers authored by Philippe A. Cassier
Since
Specialization
Citations
This map shows the geographic impact of Philippe A. Cassier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe A. Cassier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe A. Cassier more than expected).
Fields of papers citing papers by Philippe A. Cassier
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Philippe A. Cassier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe A. Cassier. The network helps show where Philippe A. Cassier may publish in the future.
Co-authorship network of co-authors of Philippe A. Cassier
This figure shows the co-authorship network connecting the top 25 collaborators of Philippe A. Cassier. A scholar is included among the top collaborators of Philippe A. Cassier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe A. Cassier. Philippe A. Cassier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Corbaux, Pauline, Armelle Vinceneux, Hélène Vanacker, et al.. (2024). Patients’ selection and trial matching in early-phase oncology clinical trials. Critical Reviews in Oncology/Hematology. 196. 104307–104307.
2.
Baurain, J.F., Antoîne Italiano, Madona Sakkal, et al.. (2024). 1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors. Annals of Oncology. 35. S692–S692.
3.
Vieito, María, Ezra Y. Rosen, Jordi Rodón, et al.. (2024). 160TiP A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab. Annals of Oncology. 35. S71–S72.
4.
Vieito, María, Ezra Y. Rosen, Jordi Rodón, et al.. (2024). 612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors. Annals of Oncology. 35. S490–S491.
5.
Burns, Timothy F., Konstantin H. Dragnev, Yutaka Fujiwara, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(16_suppl). 8510–8510.
6.
Fujiwara, Yutaka, Timothy F. Burns, Konstantin H. Dragnev, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(23_suppl). 195–195.
7.
Gomez‐Roca, Carlos, Sylvie Chabaud, Céline Rodriguez, et al.. (2024). The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Science Translational Medicine. 16(731). eadd1834–eadd1834.
8.
Negrão, Marcelo V., Philippe A. Cassier, Benjamin Solomon, et al.. (2023). MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors. Journal of Thoracic Oncology. 18(11). S117–S118.
9.
Wirth, Lori J., Vivek Subbiah, Francis P. Worden, et al.. (2023). 2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001. Annals of Oncology. 34. S1147–S1148.
10.
Cassier, Philippe A., Claire Cropet, Clélia Coutzac, et al.. (2023). 1684TiP PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer. Annals of Oncology. 34. S922–S922.
11.
Magné, Nicolas, Jérôme Fayette, Élisabeth Daguenet, et al.. (2021). Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub‐analysis of the ProfiLER protocol. Head & Neck. 43(12). 3899–3910.
12.
Jones, Robin L., César Serrano, Margaret von Mehren, et al.. (2021). Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer. 145. 132–142.
13.
Brahmi, Mehdi, Philippe A. Cassier, Armelle Dufresne, et al.. (2020). Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). PLoS ONE. 15(5). e0233046–e0233046.
14.
Cardot‐Ruffino, Victoire, Véronique Chauvet, Nicolas Chuvin, et al.. (2020). Generation of an Fsp1 (fibroblast‐specific protein 1)‐Flpo transgenic mouse strain. genesis. 58(5). e23359–e23359.
15.
Salvagno, Camilla, Metamia Ciampricotti, Cheei‐Sing Hau, et al.. (2019). Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature Cell Biology. 21(4). 511–521.
16.
Schmid, Peter, Cristina Cruz, Fadi S. Braiteh, et al.. (2017). Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Research. 77(13_Supplement). 2986–2986.
17.
Italiano, Antoîne, Valérie Laurence, Nicolas Penel, et al.. (2017). A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. Scientific Reports. 7(1). 17917–17917.
18.
Infante, Jeffrey R., Philippe A. Cassier, John F. Gerecitano, et al.. (2016). A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 22(23). 5696–5705.
19.
Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671.
20.
Cassier, Philippe A., et al.. (2008). Trabectedin and its potential in the treatment of soft tissue sarcoma. SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Annick D. Van den Abbeele Breakdown of academic impact, for papers by Didier Cupissol Breakdown of academic impact, for papers by Sant P. Chawla Breakdown of academic impact, for papers by Emmanuelle Bompas Breakdown of academic impact, for papers by Scott M. Schuetze Breakdown of academic impact, for papers by Scott H. Okuno Breakdown of academic impact, for papers by Talia Golan Breakdown of academic impact, for papers by CDM Fletcher Breakdown of academic impact, for papers by Manuel Rodriguez‐Justo Breakdown of academic impact, for papers by Jonathan C. Trent